Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
ElevateBio is riding strong momentum (~21% 21‑day gain, price ~20% above 21‑day SMA and a recent 52‑week high) after positive Phase 1b ENABLE data for ELVN‑001 (MMR ~69% at 24 weeks, durable responses) and clear plans for Phase 3; clustered late‑stage hematology catalysts plus a solid cash runway make it a high‑volatility but attractive near‑term clinical momentum trade.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: • Higher lows • Resistance cap • Support zone Support Level: $50.0-$50.8 Resistance Level: $54.33 Over the last month, ELVN remains in a constructive uptrend with higher lows, but upside is still capped near $54.33 while $50.0-$50.8 is the key near-term support zone.
Sentiment & News
Key News Insights: • Insider profit-taking • Clinical progress • Sharp rally ELVN rose on early cancer-drug progress, but recent insider selling by OrbiMed and others signals some profit-taking after a sharp rally.
AI Summary
ELVN has materially de-risked its survival with a $452M cash position and clearer Phase 3 alignment for ELVN-001, but the stock now looks priced ahead of pivotal proof, so the investable thesis hinges on whether 2026 data can convert this improved balance-sheet story into true late-stage validation.
Description
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule kinase inhibitors for cancer treatment. Its lead programs include ELVN-001, in a Phase 1 study for chronic myeloid leukemia, and ELVN-002, recently activated in a Phase 1 trial for tumors with HER2 alterations; the company is headquartered in Boulder, Colorado.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 26 | Apr 2 | ELVN | Enliven Therapeutics, Inc. | ElevateBio is riding strong momentum (~21% 21‑day gain, price ~20% above 21‑day SMA and a recent 52‑week high) after positive Phase 1b ENABLE data for ELVN‑001 (MMR ~69% at 24 weeks, durable responses) and clear plans for Phase 3; clustered late‑stage hematology catalysts plus a solid cash runway make it a high‑volatility but attractive near‑term clinical momentum trade. | Closed | -1.2% |